The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2023-09-29
DOI
10.1080/17512433.2023.2262673
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mirvetuximab Soravtansine: First Approval
- (2023) Young-A Heo DRUGS
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
- (2023) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer
- (2023) Andrea Giannini et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- (2023) Lucy Gilbert et al. GYNECOLOGIC ONCOLOGY
- The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis
- (2023) C.S.E. Hendrikse et al. GYNECOLOGIC ONCOLOGY
- Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
- (2023) Iqra Saani et al. International Journal of Environmental Research and Public Health
- Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
- (2023) Fine Aliyuda et al. CURRENT CANCER DRUG TARGETS
- Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
- (2022) Sidrah Shah et al. International Journal of Environmental Research and Public Health
- Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
- (2022) Antonios Revythis et al. International Journal of Environmental Research and Public Health
- Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
- (2022) Rachel E Sanborn et al. Journal for ImmunoTherapy of Cancer
- NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
- (2022) Deborah K. Armstrong et al. Journal of the National Comprehensive Cancer Network
- Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
- (2022) Aruni Ghose et al. International Journal of Environmental Research and Public Health
- Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
- (2022) Kensei Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
- (2022) Xiaofan Li et al. MOLECULAR CANCER THERAPEUTICS
- Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer
- (2021) Laura M. Chambers et al. GYNECOLOGIC ONCOLOGY
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
- (2021) K.N. Moore et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-in-human Phase 1 Study of MORAb-202, An Antibody-drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-positive Advanced Solid Tumors
- (2021) Toshio Shimizu et al. CLINICAL CANCER RESEARCH
- Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance
- (2020) Abir Mukherjee et al. CANCER RESEARCH
- Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- (2020) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
- (2020) Tzu-Ting Huang et al. CANCER TREATMENT REVIEWS
- Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
- (2020) Elizabeth K. Lee et al. GYNECOLOGIC ONCOLOGY
- A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
- (2020) Clinton Yam et al. INVESTIGATIONAL NEW DRUGS
- Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress
- (2019) Qingyu Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death
- (2019) Lia Tesfay et al. CANCER RESEARCH
- A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
- (2019) Shunji Takahashi et al. INVESTIGATIONAL NEW DRUGS
- Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
- (2018) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity
- (2018) Xin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J A Ledermann et al. ANNALS OF ONCOLOGY
- Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
- (2017) Lainie P. Martin et al. GYNECOLOGIC ONCOLOGY
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions
- (2016) Angela Musella et al. CHEMOTHERAPY
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
- (2016) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
- (2016) Jose F. Ponte et al. NEOPLASIA
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
- (2015) Daniel J. O'Shannessy et al. Oncotarget
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
- (2012) Ilan Bruchim et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
- (2012) Michelle K. Y. Siu et al. PLoS One
- Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease
- (2012) Daniel J O’Shannessy et al. SpringerPlus
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
- (2011) Maurie Markman Cancer Management and Research
- Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube
- (2010) Richard Wyn Griffiths et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now